National Bank of Canada
RGNX icon

National Bank of Canada’s Regenxbio RGNX Stock Holding History

National Bank of Canada’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-68,000
Closed -$713K – 3165
2024
Q3 		$713K Buy
+68,000
New +$829K ﹤0.01% 1155

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's RGNX Position: Q4 2024 in Review

National Bank of Canada sold out of Regenxbio (RGNX) in Q4 2024, closing a stake of 68,000 shares — an estimated $713K sold.

National Bank of Canada first reported a position in RGNX in Q3 2024 and held it in 1 quarter. The position peaked at $713K in Q3 2024. 177 funds tracked by Wall St. Rank hold RGNX as of Q4 2024.

  • National Bank of Canada reported no remaining Regenxbio position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 68,000 Regenxbio shares in Q4 2024, an estimated $713K.
  • National Bank of Canada first reported a position in Regenxbio in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Regenxbio position peaked at $713K in Q3 2024.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.